These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20869877)

  • 1. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
    Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
    Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
    Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC.
    Di Pierro D; Rizzello A; Cicoria G; Lodi F; Marengo M; Pancaldi D; Trespidi S; Boschi S
    Appl Radiat Isot; 2008 Aug; 66(8):1091-6. PubMed ID: 18226535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabelling DOTA-peptides with 68Ga.
    Breeman WA; de Jong M; de Blois E; Bernard BF; Konijnenberg M; Krenning EP
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):478-85. PubMed ID: 15655678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
    Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
    Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
    Petrik M; Laznickova A; Laznicek M; Zalutsky MR
    Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
    Hainsworth JE; Mather SJ
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with
    Prince D; Rossouw D; Davids C; Rubow S
    Mol Imaging Biol; 2017 Dec; 19(6):817-824. PubMed ID: 28341976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
    Mukherjee A; Lohar S; Dash A; Sarma HD; Samuel G; Korde A
    J Labelled Comp Radiopharm; 2015 Apr; 58(4):166-72. PubMed ID: 25765604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota.
    Försterová M; Petrík M; Láznicková A; Láznícek M; Hermann P; Lukes I; Melichar F
    Appl Radiat Isot; 2009 Jan; 67(1):21-9. PubMed ID: 18951809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
    Das T; Chakraborty S; Banerjee S; Venkatesh M
    Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.
    Huclier-Markai S; Kerdjoudj R; Alliot C; Bonraisin AC; Michel N; Haddad F; Barbet J
    Nucl Med Biol; 2014 May; 41 Suppl():e36-43. PubMed ID: 24361353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.
    Asti M; Tegoni M; Farioli D; Iori M; Guidotti C; Cutler CS; Mayer P; Versari A; Salvo D
    Nucl Med Biol; 2012 May; 39(4):509-17. PubMed ID: 22172388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
    Deshmukh MV; Voll G; Kühlewein A; Mäcke H; Schmitt J; Kessler H; Gemmecker G
    J Med Chem; 2005 Mar; 48(5):1506-14. PubMed ID: 15743193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
    Albert R; Smith-Jones P; Stolz B; Simeon C; Knecht H; Bruns C; Pless J
    Bioorg Med Chem Lett; 1998 May; 8(10):1207-10. PubMed ID: 9871736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.
    Schottelius M; Reubi JC; Eltschinger V; Schwaiger M; Wester HJ
    J Med Chem; 2005 Apr; 48(8):2778-89. PubMed ID: 15828816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc.
    Pruszyński M; Majkowska-Pilip A; Loktionova NS; Eppard E; Roesch F
    Appl Radiat Isot; 2012 Jun; 70(6):974-9. PubMed ID: 22464928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.